Geoffrey A. Holdgate

Author

Also Known As

G A Holdgate, G. Holdgate, G.A. Holdgate, Geoff A Holdgate, Geoff A. Holdgate, Geoff Holdgate, Geoffrey A Holdgate, Geoffrey A. Holdgate, Geoffrey Holdgate, Geoffry Holdgate

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)AstraZeneca (Sweden)AstraZeneca (United States)Newcastle University University of Manchester

About

Geoffrey A. Holdgate is an author at AstraZeneca (United Kingdom) specializing in medicine, biochemistry, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	16	1.5K
2	Biochemistry	12	12	1K
3	Natural Sciences	9	9	861
4	Engineering	5	5	208
5	Biomolecular Engineering	1	1	15

Geoffrey A. Holdgate

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Epidermal growth factor receptor tyrosine kinase Walter H.J. Ward, Peter N. Cook, Anthony M. Slater, Biochemical Pharmacology Signal TransductionReceptor Tyrosine KinaseMedicineCell BiologyCell Signaling	1994	261
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530 Tim P. Green, Mike Fennell, Robin Whittaker, Molecular Oncology	2009	254
The Entropic Penalty of Ordered Water Accounts for Weaker Binding of the Antibiotic Novobiocin to a Resistant Mutant of DNA Gyrase: A Thermodynamic and Crystallographic Study Geoffrey A. Holdgate, Alan Riboldi‐Tunnicliffe, Walter H.J. Ward, Biochemistry Molecular BiologyAntibiotic NovobiocinWater MoleculesAntibiotic ResistanceHeat Capacity	1997	206
Design and Synthesis of Novel Lactate Dehydrogenase A Inhibitors by Fragment-Based Lead Generation Richard A. Ward, C. Brassington, Alexander L. Breeze, Journal of Medicinal Chemistry Aldo-keto ReductaseMolecular BiologyLead IdentificationChemical BiologyMedicinal Chemistry	2012	169
Kinetic and Structural Characteristics of the Inhibition of Enoyl (Acyl Carrier Protein) Reductase by Triclosan Walter H.J. Ward, Geoffrey A. Holdgate, Siân Rowsell, Biochemistry Structural CharacteristicsAcyl Carrier ProteinBiochemistryNatural SciencesEnzyme Catalysis	1999	159
Potent and selective bivalent inhibitors of BET bromodomains Michael J. Waring, Huawei Chen, Alfred A. Rabow, Nature Chemical Biology Medicinal ChemistrySelective Bivalent InhibitorsMedicineDrug DevelopmentPharmacology	2016	134
Making cool drugs hot: isothermal titration calorimetry as a tool to study binding energetics. Geoffrey A. Holdgate PubMed EngineeringChemical AnalysisDifferential Scanning CalorimetryExperimental ThermodynamicsChemistry	2001	102
Methyl-Thiazoles: A Novel Mode of Inhibition with the Potential to Develop Novel Inhibitors Targeting InhA in Mycobacterium tuberculosis Pravin S. Shirude, Prashanti Madhavapeddi, Maruti Naik, Journal of Medicinal Chemistry Molecular BiologyChemical BiologyEnzymatic ModificationDrug ResistanceMedicinal Chemistry	2013	99
Prevention of MKK6-Dependent Activation by Binding to p38α MAP Kinase Jane E. Sullivan, Geoffrey A. Holdgate, Douglas A. Campbell, Biochemistry Mkk6-dependent ActivationDrug TargetMolecular RegulationChemical BiologyMedicinal Chemistry	2005	89
Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase Tobias Klein, Navratna Vajpai, Jonathan J. Phillips, Nature Communications	2015	74

Page 1